First Allied Advisory Services Inc. boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 13.0% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 102,994 shares of the biopharmaceutical company’s stock after acquiring an additional 11,824 shares during the quarter. First Allied Advisory Services Inc.’s holdings in Gilead Sciences were worth $7,287,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Penserra Capital Management LLC lifted its holdings in shares of Gilead Sciences by 9.5% in the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 144 shares during the period. American Beacon Advisors Inc. acquired a new position in shares of Gilead Sciences in the 1st quarter valued at about $143,000. Harel Insurance Investments & Financial Services Ltd. lifted its holdings in shares of Gilead Sciences by 29.3% in the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 480 shares during the period. Sterling Investment Advisors Ltd. acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at about $184,000. Finally, Truepoint Inc. acquired a new position in shares of Gilead Sciences in the 2nd quarter valued at about $204,000. 76.23% of the stock is owned by institutional investors.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $73.09 on Tuesday. The stock has a market capitalization of $95,450.00, a P/E ratio of 7.86, a PEG ratio of -1.26 and a beta of 1.13. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be given a $0.52 dividend. The ex-dividend date is Thursday, December 14th. This represents a $2.08 annualized dividend and a yield of 2.85%. Gilead Sciences’s payout ratio is 23.66%.
In related news, CFO Robin L. Washington sold 51,820 shares of the stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $85.00, for a total value of $4,404,700.00. Following the completion of the transaction, the chief financial officer now directly owns 43,352 shares in the company, valued at $3,684,920. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Gregg H. Alton sold 25,000 shares of the stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $82.65, for a total value of $2,066,250.00. The disclosure for this sale can be found here. Insiders sold 458,486 shares of company stock valued at $35,190,731 over the last quarter. 1.30% of the stock is currently owned by company insiders.
A number of research firms recently weighed in on GILD. Argus raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price target for the company in a report on Thursday, August 31st. BidaskClub cut Gilead Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Vetr cut Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $82.15 price target for the company. in a report on Monday, August 28th. Wells Fargo & Company upped their price target on Gilead Sciences from $73.00 to $81.00 and gave the stock a “market perform” rating in a report on Wednesday, September 6th. Finally, Oppenheimer began coverage on Gilead Sciences in a report on Thursday, October 5th. They issued a “market perform” rating for the company. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $85.22.
WARNING: “First Allied Advisory Services Inc. Raises Holdings in Gilead Sciences, Inc. (GILD)” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2017/12/05/first-allied-advisory-services-inc-raises-holdings-in-gilead-sciences-inc-gild.html.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
What are top analysts saying about Gilead Sciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Gilead Sciences Inc. and related companies.